INDP News and Press, Indaptus Therapeutics Inc. From 09/04/25

Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics...

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 27 th Annual Global Investment Conference. The conference is being held on Septemb...

2025-08-13 16:23:07 ET More on Indaptus Therapeutics Indaptus Therapeutics to execute 1-for-28 reverse stock split Indaptus Therapeutics announces sale of $2.3M of convertible notes, warrants Seeking Alpha’s Quant Rating on Indaptus Therapeutics Read...

2025-08-13 13:16:38 ET More on Indaptus Therapeutics Indaptus Therapeutics to execute 1-for-28 reverse stock split Indaptus Therapeutics announces sale of $2.3M of convertible notes, warrants Seeking Alpha’s Quant Rating on Indaptus Therapeutics Histor...

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for ...

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...

Indaptus Therapeutics Inc. (INDP) is expected to report for Q2 2025

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the additional sale of approximately $3.4 million in ...

2025-06-25 07:57:37 ET More on Indaptus Therapeutics Indaptus Therapeutics announces sale of $2.3M of convertible notes, warrants Indaptus Therapeutics GAAP EPS of -$0.32 misses by $0.14 Seeking Alpha’s Quant Rating on Indaptus Therapeutics Historical ...

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Board of Dire...